The European Pharmacogenetic Opioid Study (EPOS) of a large series of European cancer patients treated with opioids was carried out to assess the influence of genetics on cancer pain relief. As response to opioid therapy was associated with the patients' country of origin, we tested whether population stratification might represent a confounding factor in the analysis of genetic control of response to opioid therapy. From the whole EPOS series representing 2294 patients' genotypes for 379 single-nucleotide polymorphisms (SNPs), we extracted 117 autosomal SNPs with minor allele frequency40.28 to obtain highly informative genetic markers, and analyzed the SNPs in 1724 individuals showing o20% missing genotypes. Use of the AWclust program to detect clusters of genetically related individuals in the EPOS series showed that the 117-SNP panel distinguished four main European subgroups statistically associated with ethnicity, but not with country of origin or with the pain relief phenotype. Subethnic European groups of genetically related individuals exist that can be correctly identified using an B100-SNP panel. Such genetic clustering may control for admixture in association studies and may allow discrimination between genetic and environmental effects on phenotypes showing association with country of origin, as in the case of pain relief.
Introduction
Large European studies of environmental and genetic factors affecting the risk of several diseases have been made possible by research consortia, such as The Wellcome Trust Case-Control Consortium (WTCCC), as well as biomedical research programs of the European Commission (http://cordis.europa.eu/fp7/ home_en.html). Multicentric studies in Europe provide the obvious advantage of analyzing large populations from different countries, thus increasing the statistical power of the studies and the relevance of the results beyond those obtained by relatively small studies in a single country. However, the results of such large studies may be confounded by differences in population genetic structure and substructure, leading to either false-positive or false-negative associations. Similar considerations apply to multicentric studies and/or programs carried out in the United States or in other large countries, for example, Canada or China.
One example of a multinational study carried out in Europe is the European Pharmacogenetic Opioid Study (EPOS). In this study, significant differences were observed among countries in several key clinical outcomes, and therefore, analyses were stratified with respect to country. 1 These differences could be due to different organization of the healthcare system, leading to a variable case mix and to differences in treatment strategies. Genetic heterogeneity among patients from different countries might also account for the observed differences.
One promising approach to control for population heterogeneity in association studies is the detection of genetic relatedness of participating individuals, by taking into account differences in allele frequencies of specific genetic markers in groups of individuals in the countries participating in the study. Recent studies have led to the identification of single-nucleotide polymorphism (SNP) subsets that can be useful in ascertaining population genetic structure, 2,3 even when SNP panels are small. 4 ,5
Herein, we tested the EPOS series for genetic heterogeneity and relatedness among the participating individuals. Indeed, it is important to know whether genetic variations among individuals from different countries would bias a combined analysis in multicentric studies.
Subjects and methods

Subjects
The EPOS represents a multicenter effort to examine symptoms and pharmacology related to the use of opioids, with the aim of elucidating the influence of genetics on the efficacy of opioids in treating cancer pain and broadening the scientific basis for better individual pain treatment. The study included 2294 cancer patients treated with opioids for moderate or severe pain and recruited from 17 centers of 11 European countries. The study population included four ethnic groups: (i) Caucasian, including Hispanic, (ii) African, (iii) Oriental and (iv) others. Pain relief was measured using an 11-point numerical rating scale (in increments of 10%), from 0% representing 'no pain relief' to 100% or 'complete pain relief', using the Brief Pain Inventory, a robust and psychometric validated method to assess the severity of pain. 6 Opioids administered to 45% of patients included morphine, oxycodone and fentanyl; further details about the EPOS series, including opioid doses, type of cancer and recruitments, are reported in Klepstad P et al. 
Genotyping
Genomic DNA was isolated from EDTA-treated whole blood using the Gentra Puregene blood kit (QIAGEN, Germantown, MD, USA) at HUNT Biobank, Levanger, Norway. Genotyping was performed by applying the SNPlex Genotyping System according to the supplier's dry DNA protocol, using universal SNPlex System kits and reagents and SNPspecific ligation probes (Applied Biosciences, Foster City, CA, USA). The SNPlex signals were analyzed using GeneMapper Software v4.0 (Applied Biosciences) followed by manual reading, quality control and data cleaning. Samples showing low-signal strength inseparable from negative controls and SNPs with inconsistent clustering on inspection were rejected before analysis and treated as missing data.
Statistical analyses
SNPs were selected using PLINK software (release 1.07), 7 which included analysis of Hardy-Weinberg equilibrium, linkage disequilibrium between SNPs and selection of SNPs based on minor allele frequency and missingness ratio. Genetic clustering analysis was carried out using the AWclust program.
8 A 1-3 gradient for either East-West or North-South was attributed to each country of origin (Supplementary Table 1 ). w 2 -Test with P-values computed with continuity correction and by Monte-Carlo simulation (2000 replicates), Kruskal-Wallis and ANOVA analyses were carried out using the Rcmdr package in R. 9 
Results
Association between pain relief phenotype and country of origin The pain relief phenotype, expressing the individual pain intensity and the extent to which pain interferes with physical and psychological functions after opioid therapy for cancer pain, showed large inter-individual variations and was strongly associated with the country of origin in the whole EPOS data set, with Italian and Greek patients showing the highest and lowest pain relief values, respectively (n ¼ 2294; Po2.2 Â 10 À16 , Kruskal-Wallis; Figure 1 ). Even after excluding Greece because of the low number of patients (n ¼ 5), statistically significant variations in pain relief phenotype were observed among several countries ( Figure 1 ). Cluster analysis shows ethnic differences in the EPOS series To test whether the statistically significant association between the variable 'country of origin' and the pain relief phenotype might derive from subethnic genetic differences among the EPOS individuals, we explored the genetic substructure of the patients. From the 2294 EPOS cancer patients genotyped for 379 SNPs, we selected autosomal SNPs based on: low missingness rate (o20%), as missing data can create artificial substructure; 10 no deviation from Hardy-Weinberg equilibrium (P40.05); absence or low linkage disequilibrium among them (r 2 o0.5, measured for SNP-SNP genotypic correlation); and high informativeness (minor allele frequency40.28, that is, heterozygosity 40 to 50%). To avoid potential false clusters that might arise from grouping together of individuals with missing genotypes, 570 individuals with low genotyping rate (o80%) were removed from the database. Analysis of the pain relief phenotype of the 570 removed subjects as compared with the remaining patients revealed a statistically significant association between the missing status and pain relief (P ¼ 0.0009). Such an association was likely due to the association of the missing status with country of origin (Po2.2 Â 10 À16 ; w 2 ), which we also detected.
Analysis of genetic clustering in the shortened EPOS data set containing 1724 individuals and 117 autosomal SNPs (Supplementary Table 2 ) using the AWclust program 8 showed no apparent sub-population clusters, and defined four main population groups (K ¼ 4) based on optimal cluster size, which maximizes the distance between the observed and expected log of the pooled within-cluster sum of squares (Figure 2a) , and as shown by hierarchical plot ( Figure 3) ; each of the four clusters contained from 332 to 559 subjects. The second-best number of clusters defined by the AWclust software was K ¼ 16 ( Figure 2b) ; each of the 16 cluster groups contained from 71 to 155 subjects.
To verify that the distribution of the individuals into clusters reflected the genetic ancestry of the population, we analyzed the association of the cluster groups (K ¼ 4 or K ¼ 16) with ethnicity. As expected, we found a statistically significant association with ethnic group when considering either By coding the country of origin as a quantitative 1 to 3 East-West and North-South gradient score, we found a weak statistically significant association between the East-West status and the K ¼ 4 (P ¼ 0.019, ANOVA) but not K ¼ 16 genetic clusters, whereas a much better statistical association was observed between the North-South status and either the K ¼ 4 (P ¼ 0.005) or the K ¼ 16 (P ¼ 0.0006) cluster groups.
To examine whether the selected SNPs can control for EPOS series substructure in the association study for opioid response to cancer pain, we analyzed the association of the genetic clustering with the pain relief phenotype. No statistically significant association was found between either cluster group (K ¼ 4 or K ¼ 16) and the pain relief phenotype, indicating that the response to opioid treatment for cancer pain is not linked to the ancestral origin of the individuals.
Discussion
Our cluster analysis of EPOS individuals to determine whether the association of pain relief with country of origin might mask genetic substructures in that study showed that a relatively small number of highly informative SNPs, that is, 117, is sufficient for an adequate representation of the genetic relatedness among individuals of a European complex population. Indeed, clustering analysis using these genetic markers in the EPOS series clearly defined four main groups. Accordingly, a recent study demonstrated that a 93-SNP panel can efficiently identify continental subject groups. 4 The same research group, starting from 300 K SNPs, defined European genetic substructures using a SNP subset constituted by 3519 SNPs, although the number of main genetic groups defined by their analysis was not reported. 2 We were aware that using cancer patients (EPOS study) rather than healthy individuals may constitute a bias in cluster analysis based on genetic relatedness, if genetic factors involved in pain relief are also relevant to carcinogenesis; however, the association of genetic clusters with ethnicity, notwithstanding the small number of nonCaucasian patients, suggests that the EPOS series represents an adequate subset of a random European population deriving from the countries participating to the EPOS project.
Several studies have shown that genetic ancestry may contribute to the development of disease-related and other phenotypes. [11] [12] [13] We found no association of genetic clusters with the pain relief phenotype, suggesting that pain response to opioids is genetically intrinsic to each individual and unrelated to ancestral origin. The variability in clinical outcomes that has been found associated with the country of origin in the EPOS study may perhaps be related to variable case mix. Indeed, the access to palliative care units may vary among countries, resulting in a different proportion of severe cases and hence of the expected pain relief. Furthermore, the treatments administered for pain relief are different across European countries.
14 Also, differences among countries in blood-sample management and storage, resulting in different quality of DNAs and, consequently, of the genotyping rate, may explain the association between the missing status and the country of origin. As individuals with missing genotypes could group together to create false clusters, 10 cluster analysis based on genetic constitution requires a similar genotypic rate for all individuals; therefore, we had to remove B25% of the whole series from the analysis, because of their low genotyping rate (that is, o80%).
In the analysis if genetic factors are involved in pain relief, we should also take into consideration that opioids are administered to cancer patients (EPOS study) rather than to healthy individuals and, therefore, a bias may occur if some of the genetic factors involved in pain relief are also relevant to carcinogenesis.
In patients of the EPOS study deriving from 11 European countries, we found that country of origin is not a useful parameter to infer ancestry, probably due to factors such as internal migration and admixture. These findings suggest that patients from European countries can be analyzed altogether in association studies without the absolute requirement of stratification by genetic clusters. However, when large geographical locations were considered, genetic clusters tended to be statistically associated, in particular with the North-South gradient, in agreement with other studies that reported associations between genetic and geographic distances by examining individuals distributed in more European countries as compared with our study. 15, 16 Overall, our findings indicate that genetic clustering using SNP panels of relatively small size may represent additional information to control for population structure in association studies and to discriminate between the effects of genetics and environment on phenotypes showing association with country of origin, as in the case of pain relief. Figure 3 Dendrogram plot of the European Pharmacogenetic Opioid Study (EPOS) data set using 117 single-nucleotide polymorphisms (SNPs) and 1724 samples, calculated based on the allele sharing distance matrix between all individuals of the data set. The hierarchical plot showed that the EPOS series subdivides into four main genetic clusters (separated by the red line).
